##1. Limitations of Conventional CRISPR-Cas12a and the RNA Barrier Although the CRISPR-Cas12a system has demonstrated outstanding performance in DNA editing, it has clear limitations in directly recognizing and manipulating RNA. Because the existing guide system is optimized solely for DNA targets, researchers studying RNA virus detection or precise transcriptome regulation have had to resort to alternative enzymes instead of Cas12a, which is cumbersome.

##2. Synthetic DNA Guide (crDNA): Providing Cas12a with an RNA Map The research team succeeded in issuing new commands to the Cas12a enzyme using an innovative solution termed “synthetic DNA guide (crDNA).” By coupling specially designed crDNA to Cas12a in place of the conventional guide RNA, the enzyme was reprogrammed to seek RNA sequences rather than DNA. This complex identified and cleaved target RNA with remarkable precision while exhibiting high selectivity—showing no activity toward the original DNA targets.

##3. Broad-Spectrum Applications Spanning Diagnostics and Therapeutics The emergence of this technology has immediate impact on viral RNA detection and gene expression regulation. Its ability to capture specific sequences of rapidly mutating RNA viruses in real time can dramatically improve the accuracy and speed of diagnostic kits. Beyond laboratory proof‑of‑concept, it holds the potential to become a core tool for RNA‑based therapeutic development, positioning it to drive the next generation of the biotech market.

##4. A New Horizon for RNA Editing in the Era of Precision Medicine The crDNA‑Cas12a system is expected to reshape infectious‑disease monitoring when integrated with point‑of‑care diagnostics. Unlike permanent DNA editing, transient RNA control at the required moment minimizes off‑target concerns associated with DNA editing and enables finer regulation of cellular functions, positioning it as a “safe gene scissors” technology.